Investment Rating - The report maintains a "Recommended" rating for the company with a target price of 80 yuan [2][6]. Core Views - The company experienced a phase of performance pressure in 2025, with a revenue of 1.144 billion yuan (up 6.43%) and a net profit of 290 million yuan (down 8.64%) for the first three quarters [2]. - The company is accelerating its innovation and research and development efforts, with significant product launches expected to contribute to future growth [2][6]. Financial Performance Summary - **Revenue and Profitability**: - For Q3 2025, revenue was 358 million yuan (down 8.17%), and net profit was 77 million yuan (down 29.85%) [2]. - The projected total revenue for 2024A is 1.41 billion yuan, with a growth rate of 48.2%, and expected to reach 2.34 billion yuan by 2027E [7]. - **Profit Forecast**: - The forecasted net profit for 2025E is 394 million yuan, with a growth rate of 1.5%, increasing to 571 million yuan by 2027E [7]. - **Earnings Per Share (EPS)**: - The EPS is projected to be 2.01 yuan for 2024A, increasing to 2.95 yuan by 2027E [7]. Product and Market Insights - **Product Performance**: - The artificial lens and contact lens businesses faced temporary pressure due to market conditions, while the orthokeratology lens business showed robust growth [2][6]. - **Innovation and R&D**: - The company has launched two significant products in 2025, which are expected to enhance its market position and sales potential [2][6]. Valuation and Market Position - **Valuation Metrics**: - The company is valued at approximately 155 billion yuan, with corresponding price-to-earnings (PE) ratios projected at 29, 24, and 20 for the years 2025E, 2026E, and 2027E respectively [2][6]. - **Market Capitalization**: - The total market capitalization is reported at 11.633 billion yuan [3].

Investment Rating - The report maintains a "Recommendation" rating for the company, with a target price of 24 yuan and a current price of 17.75 yuan [4][9]. Core Insights - The company reported a revenue of 3.453 billion yuan for the first three quarters of 2025, reflecting an increase of 8.52% year-on-year, while the net profit attributable to the parent company was 211 million yuan, down 17.36% [2][9]. - In Q3 2025, the company achieved a revenue of 1.190 billion yuan, up 13.40% year-on-year, but the net profit dropped significantly by 47.55% to 30 million yuan [2][9]. - The decline in profit is primarily attributed to cross-licensing patent fees impacting short-term profitability, specifically a payment of 19 million USD to Roche, which affected the net profit by approximately 136 million yuan [9]. Financial Performance Summary - The total revenue forecast for 2024A, 2025E, 2026E, and 2027E is 4.443 billion, 4.901 billion, 5.474 billion, and 6.250 billion yuan respectively, with year-on-year growth rates of 9.5%, 10.3%, 11.7%, and 14.2% [4][10]. - The net profit attributable to the parent company is projected to be 326 million, 294 million, 485 million, and 581 million yuan for the same years, with growth rates of 14.7%, -10.1%, 65.3%, and 20.0% respectively [4][10]. - The earnings per share (EPS) is expected to be 0.58, 0.52, 0.87, and 1.04 yuan for 2024A, 2025E, 2026E, and 2027E respectively [4][10]. Market Position and Competitive Landscape - The company is experiencing steady growth in both traditional and continuous glucose monitoring (CGM) businesses, with double-digit revenue growth in Q3 2025 [9]. - The company has successfully navigated patent challenges, reaching a settlement with Roche and obtaining necessary patent licenses, which is crucial for its market expansion [9]. - The report highlights the importance of ongoing innovation and intellectual property management to mitigate risks associated with patent litigation from industry giants [9].

Investment Rating - The industry investment rating is "Recommended," indicating an expected increase in the industry index exceeding the benchmark index by more than 5% in the next 3-6 months [26]. Core Insights - The insurance industry has experienced a decline in both property and life insurance premiums, with total original premium income reaching 54,833 billion yuan from January to October 2025, reflecting a year-on-year growth of 8% but a month-on-month decrease of 0.8 percentage points [8][6]. - Life insurance premiums totaled 32,748 billion yuan, with a year-on-year increase of 12% but a month-on-month decline of 0.7 percentage points [8]. - The report highlights that the sales of participating insurance and universal insurance products are expected to perform well due to favorable market conditions [8]. - The total assets of the insurance industry reached 40.6 trillion yuan by the end of October 2025, representing a year-on-year increase of 13% [8]. - The report anticipates that participating insurance will become a key product for the upcoming sales season, driven by the attractiveness of "call options" in the current market environment [8]. Summary by Sections Key Company Profit Forecasts, Valuation, and Investment Ratings - China Pacific Insurance (601601.SH) is rated "Recommended" with an expected EPS of 5.68 yuan for 2025 and a PE ratio of 6.20 [4]. - China Life Insurance (601628.SH) is also rated "Recommended" with an expected EPS of 6.34 yuan for 2025 and a PE ratio of 6.89 [4]. - China Property & Casualty Insurance (02328.HK) is rated "Recommended" with an expected EPS of 2.07 yuan for 2025 and a PE ratio of 7.54 [4]. - China Taiping Insurance (00966.HK) is rated "Recommended" with an expected EPS of 3.00 yuan for 2025 and a PE ratio of 5.28 [4]. Industry Overview - The report indicates that the cumulative premium growth rates for both property and life insurance have declined, with life insurance premiums showing a year-on-year increase of 12% but a month-on-month decrease of 5.2% in October [8]. - The report notes that the health and accident insurance segments have seen growth, but their growth rates have also decreased month-on-month [8]. - The report emphasizes that the market's favorable conditions are expected to enhance the sales of participating insurance products [8]. Asset Changes - By the end of October 2025, the insurance industry had total assets of 40.6 trillion yuan, with life insurance companies holding 35.68 trillion yuan and property insurance companies holding 3.15 trillion yuan [8]. - The net assets of the insurance industry reached 3.81 trillion yuan, reflecting a year-on-year increase of 14.7% [8].

Investment Rating - The report maintains a "Strong Buy" rating for Shanxi Fenjiu [1][6] Core Insights - The company has established a solid foundation for steady growth, with effective order management and a focus on product innovation and market expansion [6] - The company aims to enhance its brand synergy and improve its marketing strategies to better adapt to market demands and consumer preferences [6] - The financial outlook remains positive, with projected revenue growth and stable profit margins, despite some challenges in brand collaboration and market competition [6] Financial Summary - Total revenue is projected to reach 36,011 million in 2024, with a growth rate of 12.8%, and is expected to grow to 40,011 million by 2027 [2] - Net profit attributable to shareholders is forecasted to be 12,243 million in 2024, remaining stable in 2025, and then increasing to 13,282 million by 2027 [2] - Earnings per share (EPS) is estimated at 10.04 in 2024, with slight declines in 2025 and 2026, before rising to 10.89 in 2027 [2] Market Performance - The company has shown resilience in maintaining market order and channel management, which is expected to help it navigate through economic cycles effectively [6] - The stock's target price is set at 285 yuan, compared to the current price of 192.16 yuan, indicating significant upside potential [2][6] Strategic Outlook - The company plans to focus on four key areas: national expansion, youth engagement, internationalization, and precise consumer service [6] - Product innovation and marketing strategies will be enhanced to attract younger consumers and improve brand visibility [6] - The company is committed to maintaining market order and ensuring channel cooperation, which is crucial for sustaining growth in a competitive environment [6]

Investment Rating - The industry investment rating is "Recommended," indicating an expected increase in the industry index exceeding the benchmark index by more than 5% in the next 3-6 months [22]. Core Insights - The insurance index rose by 0.21% this week, underperforming the market by 1.43 percentage points. Individual stock performances varied, with AIA up by 4.95% and China Pacific down by 3.5% [2]. - The report highlights that the risk associated with real estate investments by insurance companies is expected to be manageable, with a focus on the debt extension of Vanke [2][5]. - The report anticipates that while performance may fluctuate in the short term due to equity market trends, a growth trend is expected to continue into 2025, although 2026 may see performance pressure from investment factors [5]. Summary by Sections Market Performance - The insurance index's absolute performance over the last month is 0.8%, with a 6-month performance of 13.7% and a 12-month performance of 12.8% [8]. - The relative performance against the benchmark shows a 2.2% outperformance over one month, but underperformance of -5.5% over six months and -3.2% over twelve months [8]. Company Analysis - The report provides earnings per share (EPS) estimates for key companies, with China Life at 6.34 CNY for 2025E and China Pacific at 5.68 CNY for the same year. The price-to-earnings (PE) ratios for these companies are also provided, with China Life at 6.89x and China Pacific at 6.20x [11]. - The price-to-book (PB) ratios indicate that China Life has a PB of 1.97, while China Pacific has a PB of 1.12, both rated as "Recommended" [11]. Real Estate Investment Risk - The report analyzes the exposure of listed insurance companies to real estate investments, noting that the overall exposure remains relatively small compared to total investment assets. For instance, Ping An's real estate investment exposure is 3.5%, a decrease of 0.3 percentage points from the previous year [5]. - The report indicates that the increase in real estate investment exposure for China Pacific is primarily due to a rise in investment properties [5]. Long-term Outlook - The long-term outlook suggests that improvements in life insurance costs may drive valuation recovery, with a shift towards dividend insurance and easing solvency requirements expected to enhance long-term investment returns [5].

Group 1: Economic Outlook - CPI is expected to rise significantly from 0.2% to around 0.7% year-on-year due to food price fluctuations[3] - Industrial production growth is projected at approximately 5.3% for November, supported by external demand[4] - Exports are anticipated to increase by about 5% year-on-year in dollar terms, with imports also expected to rise by 5%[4] Group 2: Financial Indicators - New social financing is estimated at 1.6 trillion yuan, a decrease of 650 billion yuan compared to the same period last year[6] - M2 growth is expected to be around 8.0%, while M1 is projected to grow by approximately 5.6%[6] - The stock of social financing growth is forecasted to decline to about 8.3%[6] Group 3: Investment and Consumption - Fixed asset investment growth is expected to fall to around -2.4% for January to November, with real estate investment down by 15.5%[4] - Retail sales growth is projected at 2.6%, with essential consumption growing at 4.0% and subsidy-related items declining by 3.0%[22] - Real estate sales area growth is expected to be around -20% for November, with cumulative growth from January to November at -8.1%[18]

京沪社零为何背离？ ❖ 核心观点 本文聚焦各能级城市的社零表现。一线偏弱，二三线偏强的格局未变。但一线 内部，北京上海社零增速明显背离，今年前 10 个月，北京社零同比仍为-3.2%， 上海则升至 4.8%。原因或与统计因素有关，社零按"企业注册地"统计，若企 业迁移，则对应社零也会跟随迁移。据北京统计局，近期北京企业设立跨区域 经营主体明显增加，此前计入北京的社零迁移至外地，进而拖累北京社零。但 上海或在推动社零制度改革，即从此前的"企业注册地"切换至"活动发生地"， 在这一制度下，企业设立异地经营主体对上海社零影响不大，这一统计因素或 是北京、上海社零分化的重要原因之一。当然，抛开统计因素回归基本面来看， 上海市的居民消费、企业消费确实在改善，社零读数回升有基本面支撑。 ❖ "不变"：仍是一线偏弱，二三线偏强 2024 年，我们曾分析为何一线社零偏弱、三四线社零偏强，参见报告《一线城 市消费为何走弱？》、《三四线城市消费为何偏强？》，目前来看，这一趋势仍 在延续，今年前三季度，全国社零同比增长 4.5%，一线增速为 1.5%，而二线 （19 城）、三线（轧差得来）增速均在 5%左右，2024 年为-1.6 ...

策略研究 证 券 研 究 报 告 【策略月报】 从红利年化 10%看收益来源 ——多行业联合红利资产 11 月报 策略月报 2025 年 12 月 03 日 华创证券研究所 证券分析师：姚佩 邮箱：yaopei@hcyjs.com 执业编号：S0360522120004 证券分析师：吴一凡 邮箱：wuyifan@hcyjs.com 执业编号：S0360516090002 证券分析师：徐康 电话：021-20572556 邮箱：xukang@hcyjs.com 执业编号：S0360518060005 证券分析师：杨晖 证券分析师：马野 邮箱：maye@hcyjs.com 执业编号：S0360523040003 相关研究报告 邮箱：yanghui@hcyjs.com 执业编号：S0360522050001 证券分析师：欧阳予 邮箱：ouyangyu@hcyjs.com 执业编号：S0360520070001 证券分析师：韩星雨 邮箱：hanxingyu@hcyjs.com 执业编号：S0360525050001 证券分析师：单戈 邮箱：shange@hcyjs.com 执业编号：S0360522110001 证券 ...

Group 1 - The report emphasizes a shift in investment strategy for Chinese assets from a short-term focus to a long-term perspective, driven by significant changes in long-term factors and a restructuring of the valuation system [2][15][32] - It highlights the advantages of RMB assets from a global perspective, including a stable fiscal environment, a complete industrial chain, a talent pool, and attractive valuations [2][3][15] - The report identifies key points for sustaining growth, focusing on economic construction and the expansion of the middle class, indicating a transition from low prices to a new phase of recovery [2][3][15] Group 2 - The report discusses a new macro paradigm characterized by a shift from quantity-driven growth to quality-driven growth, emphasizing efficient operations and high return on equity (ROE) [3][16] - It notes the completion of the transition from old to new economic drivers, with a decline in the real estate sector's drag on A-share ROE, and a focus on technology and manufacturing sectors [3][16] - The report mentions a change in the investment landscape, where equities are seen as a preservation tool rather than just a financing instrument, leading to improved asset quality and reduced volatility [3][16] Group 3 - The analysis predicts a "re-inflation" phase in the second half of the bull market, driven by improved liquidity, supply-side adjustments, and demand stimulation, with a projected net profit growth of 11.1% for non-financial A-shares in 2026 [4][17] - It outlines the expected performance of the stock market, with a neutral return of 7.8% and an optimistic scenario suggesting a 31.5% return, indicating a strong bullish sentiment [4][17] - The report emphasizes the importance of tracking service consumption subsidies and housing price stabilization as key demand drivers [4][17] Group 4 - The report advocates for a focus on growth quality factors and large-cap growth stocks, suggesting that high-quality growth will outperform pure cash dividends in the current market environment [5][18] - It identifies key sectors for investment, including finance, high-end manufacturing, electronics, and consumer goods, which are expected to lead the market upward [5][18] - The report highlights the importance of technology and cyclical sectors, as well as the potential for overseas expansion and the real estate consumption chain to drive future growth [5][18] Group 5 - The report recommends a diversified investment strategy focusing on four key areas: technology innovation, cyclical sectors, overseas expansion, and the real estate consumption chain [6][19] - It emphasizes the importance of identifying high-potential stocks, referred to as "ten-bagger" opportunities, and building a core portfolio of quality large-cap growth stocks [6][19] - The report suggests that the current market environment presents unique opportunities for investors to capitalize on structural transformations and growth potential [6][19]

Core Insights - The report emphasizes the dual-driven business model of the insurance industry, focusing on both assets and liabilities, with a long-term outlook on liability cost optimization driving valuation recovery [8][9] - The insurance sector is currently at a cyclical turning point, with improving operational quality and a focus on cost reduction strategies, particularly in life insurance [9][10] Industry Overview - The insurance sector's total market capitalization is approximately 32,040.19 billion, with a circulating market value of 22,048.26 billion [4] - The report indicates a significant increase in the insurance index, with a 13.8% rise over the past 12 months, although it has underperformed relative to the broader market in the last six months [5] Company Profit Forecasts and Valuations - Key companies such as China Life, China Pacific, and Ping An are projected to have varying EPS growth rates, with China Life expected to see EPS of 6.34 in 2025 and 4.10 in 2026, while Ping An is forecasted to reach 8.02 in 2025 and 8.83 in 2026 [3] - The report maintains a "Buy" recommendation for several companies, including China Life and China Pacific, based on their projected performance and valuation metrics [3] Investment Themes - The report highlights the importance of the "cost reduction trifecta" in life insurance, focusing on product innovation, channel expansion, and dynamic adjustment of preset interest rates [8][9] - In property insurance, the "reporting and operation integration" is expected to optimize costs and enhance profitability, particularly in non-auto insurance segments [9][10] Short-term and Long-term Outlook - Short-term performance is closely tied to equity market trends, with expectations of continued growth in 2025, but potential pressure on performance in 2026 due to investment factors [9][10] - Long-term, the report anticipates that improvements in life insurance costs will drive valuation recovery, with a projected NBV growth rate of over 15% for listed insurance companies in 2026 [9][10] Regulatory Environment - The introduction of a dynamic adjustment mechanism for preset interest rates is expected to alleviate liability costs and enhance the attractiveness of dividend insurance products [24][38] - Recent regulatory guidance aims to stabilize dividend levels in insurance products, preventing excessive competition and ensuring sustainable growth [38][39]